KalVista Announces Positive Interim Data for Hereditary Angioedema Drug

Pharmaceutical company reports promising Phase 3 trial results for EKTERLY treatment in pediatric patients.

Mar. 30, 2026 at 6:08pm

Got story updates? Submit your updates here. ›

KalVista Pharmaceuticals has announced new interim results from its KONFIDENT-KID clinical trial evaluating the safety and efficacy of its EKTERLY (sebetralstat) treatment for hereditary angioedema in pediatric patients. The company reported positive data from the ongoing Phase 3 study, indicating the drug candidate is showing promise in managing symptoms of this rare genetic disorder.

Why it matters

Hereditary angioedema is a potentially life-threatening condition characterized by recurrent episodes of severe swelling. Effective treatments are limited, especially for younger patients. Positive interim results from KalVista's late-stage trial suggest EKTERLY could provide a new therapeutic option to help manage this debilitating disease in the pediatric population.

The details

The KONFIDENT-KID trial is evaluating EKTERLY, an oral plasma kallikrein inhibitor, in children and adolescents aged 6 to 17 with hereditary angioedema. The interim analysis showed the drug met its primary endpoint of reducing the rate of angioedema attacks compared to placebo. KalVista also reported EKTERLY was generally well-tolerated, with a safety profile consistent with previous studies in adult patients.

  • The KONFIDENT-KID trial is an ongoing Phase 3 study.

The players

KalVista Pharmaceuticals

A clinical-stage pharmaceutical company focused on developing treatments for hereditary angioedema and other plasma kallikrein-mediated diseases.

EKTERLY (sebetralstat)

KalVista's oral plasma kallikrein inhibitor drug candidate for the treatment of hereditary angioedema.

Got photos? Submit your photos here. ›

What they’re saying

“We are very encouraged by these positive interim results from the KONFIDENT-KID trial, which demonstrate the potential of EKTERLY to provide an important new treatment option for children and adolescents living with this debilitating disease.”

— Andrew Crockett, Chief Executive Officer of KalVista Pharmaceuticals

What’s next

KalVista plans to continue the KONFIDENT-KID trial and submit the full data for regulatory review once the study is completed.

The takeaway

The promising interim results from KalVista's pediatric hereditary angioedema trial suggest EKTERLY could become an important new treatment option to help manage this rare and serious condition in younger patients, for whom effective therapies have been limited.